The Cell and Gene Therapy Catapult (CGT Catapult) announced it has licensed data from its pluripotent stem cell development programme, Cell Plasticity, to Japanese food and amino acid company Ajinomoto.
Through the use of processes and analytical data from CGT Catapult’s programme, Ajinomoto was able to evaluate the adherent expansion of CGT’s human induced pluripotent stem cell (iPSC) line CGT-RCiB10, in different culture systems.
CGT Catapult is dedicated to supporting the growth of the UK cell and gene therapy industry, bridging the gap between scientific research and commercialisation.
As part of supporting this growth CGT Catapult has been working to develop scalable processing platforms of pluripotent stem cells and their derivatives, and supporting the translation of research into commercially viable advanced therapy medicinal products.
The continued focus from CGT on developing novel products, such as the pluripotent stem cell programme, provides the organisation with the opportunity to collaborate with academic and commercial partners across the world in some of the most innovative and promising areas of medical research.
Keith Thompson, CEO at Cell and Gene Therapy Catapult, said: “We are thrilled that our research continues to be sought after by organisations across the globe. The licensing of this data to Ajinomoto highlights the benefit and skills we continue to bring to these organisations and through them, how the Catapult is able to contribute to the advancement of technologies and medicines of the future.”
CGT Catapult works with partners in academia and industry to ensure life changing therapies can be developed for use in health services throughout the world.
The data use by Ajinomoto highlights the global reach of Catapult programmes, and the requirement of globally significant organisations in the cell and gene therapy industry.
